Unión Europea - islandés - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - heila-og mænusigg, köstum tilkynnt - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Unión Europea - islandés - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - Önnur lyf í taugakerfinu - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - methylphenidatum hýdróklóríð; methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - pramipexolum díhýdróklóríð - tafla - 0,18 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - pramipexolum díhýdróklóríð - tafla - 0,088 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 10 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 18 mg